보고서 요약(국문)

시장 개요
전 세계 아미노글리코사이드 시장은 2022년 16억 3,640만 달러 규모에 달했으며, 2030년까지 22억 220만 달러에 이를 것으로 예상되어 높은 성장세를 보일 전망입니다. 전 세계 아미노글리코사이드 시장은 예측 기간(2023-2030년) 동안 연평균 3.8%의 성장률을 기록할 것으로 예상됩니다.
전 세계 아미노글리코사이드 시장은 심각한 세균 감염 치료에 중점을 둔 제약 산업의 핵심 분야입니다. 아미노글리코사이드는 병원, 클리닉, 연구실에서 널리 사용되는 중요한 항생제입니다. 최근 시장 동향은 복합제에 대한 수요 증가와 새로운 제형 개발에 대한 관심이 두드러지게 나타나고 있습니다. 전 세계 아미노글리코사이드 시장의 주요 발전 사항으로는 연구 개발 활동, 규제 승인, 수의학 분야에서의 활용 증가 등이 있습니다.
세균 감염의 증가, 고령화 인구 증가, 항생제 사용량 증가는 전 세계 아미노글리코사이드 시장 성장을 견인하는 요인입니다. 고령 인구의 증가로 아미노글리코사이드계 항생제에 대한 수요가 증가하고 있습니다. 세계보건기구(WHO)의 2022년 전망에 따르면, 60세 이상 인구는 급격히 증가할 것으로 예상됩니다. 2030년에는 전 세계 인구 6명 중 1명이 60세 이상이 될 것이며, 이 연령대의 인구는 2020년 10억 명에서 14억 명으로 증가할 것으로 추산됩니다.

시장 동향
결핵 발병률 증가가 세계 아미노글리코사이드 시장 성장을 견인하고 있습니다.

결핵 발병률 증가는 세계 아미노글리코사이드 시장의 상당한 성장을 이끄는 주요 요인 중 하나입니다. 아미노글리코사이드와 같은 강력한 항생제는 심각한 세균성 질환인 결핵을 효과적으로 치료하는 데 필수적입니다. 특히 개발도상국에서 결핵 발병률이 증가함에 따라 아미노글리코사이드에 대한 수요가 증가하고 있습니다.

예를 들어, 미국 질병통제예방센터(CDC)의 2023년 보고서에 따르면, 2022년 미국에서는 8,300건의 결핵(TB) 사례가 보고되었으며, 이는 인구 10만 명당 2.5건의 발생률에 해당합니다. 이는 2021년에 보고된 7,874건에서 소폭 증가한 수치입니다. 2022년 결핵 발생률은 인구 10만 명당 2.5건으로 유지되었습니다.
수의학 분야에서 아미노글리코사이드에 대한 수요 증가가 세계 아미노글리코사이드 시장의 성장을 견인하고 있습니다.
수의학 분야에서 아미노글리코사이드의 사용은 지속적으로 확대되어 시장 참여자들에게 수익성 있는 기회를 제공하고 있습니다. 가축, 반려동물 및 양식업에서 아미노글리코사이드는 세균 감염 치료에 흔히 사용됩니다. 가금류 및 돼지 사육에서는 사료 또는 음용수에 첨가하여 투여합니다.

예를 들어, 마이코플라스마와 대장균은 가금류에서 아미노글리코사이드계 항생제로 치료해야 하는 가장 흔한 호흡기 감염 원인균입니다. 동물은 대장균, 프로테우스균, 슈도모나스균, 살모넬라균, 시겔라균, 세라티아균, 엔테로박터균 등의 세균 감염 치료를 위해 아미노글리코사이드계 항생제를 사용할 수 있습니다. 이러한 이유로 세균 감염 치료에 대한 수의학 분야의 수요 증가는 예측 기간 동안 전 세계 아미노글리코사이드 시장 성장을 견인할 것입니다.
그러나 항생제 내성 발생은 전 세계 아미노글리코사이드 시장 성장을 저해하는 요인입니다.
항생제 내성은 세균이 항생제의 효과에 저항하는 능력으로, 세균 감염 치료에 항생제를 사용할 수 없게 만듭니다. 아미노글리코사이드계 항생제의 장기간 부적절한 사용은 이러한 항생제에 내성을 가진 세균 균주의 발생에 기여하여 항생제의 효능을 감소시키고 있습니다.
예를 들어, 메티실린 내성 황색포도상구균(MRSA)과 광범위 베타락탐 분해효소(ESBL) 생성 세균은 아미노글리코사이드계 항생제에 내성을 보이고 있습니다. 감염 환자의 아미노글리코사이드 내성률, 표현형 및 기전이 모두 보고되었습니다. MRSA 및 ESBL 생성균과 같은 항생제 내성균은 공중 보건에 대한 위협으로 대두되고 있습니다.
COVID-19 영향 분석
COVID-19 발생은 전 세계 아미노글리코사이드 산업에 상당한 영향을 미쳤습니다. 팬데믹으로 인해 전 세계 공급망이 교란되고 아미노글리코사이드 산업을 포함한 다양한 산업 분야의 상품 및 서비스 수요가 감소했습니다. COVID-19가 아미노글리코사이드 시장에 미치는 가장 중요한 영향 중 하나는 공급망 교란으로 인해 아미노글리코사이드 항생제 생산량이 감소한 것입니다.
또한, 팬데믹으로 인해 사람들이 건강에 대한 우려가 커지고 감염 및 장기 입원을 피하기 위해 적절한 처방을 받으면서 항생제 사용량이 증가했습니다. 그러나 아미노글리코사이드는 COVID-19 퇴치에 특별한 이점을 가질 수 있습니다. 미국 국립 의학 도서관에서 2021년에 발표한 논문에 따르면, 아미노글리코사이드는 SARS-CoV-2 항바이러스제로서의 잠재력을 가지고 있습니다. 시험관 내 실험에서 아미노글리코사이드계 항생제인 하이그로마이신 B(hygB)와 네오마이신이 생쥐 간염 바이러스(MHV)를 억제하는 것으로 나타났습니다. 또한, hygB는 소와 고양이 코로나바이러스에 대해서도 활성을 보였습니다.
러시아-우크라이나 분쟁 분석
러시아와 우크라이나 간의 분쟁은 세계 아미노글리코사이드 시장에 상당한 영향을 미칠 것으로 예상됩니다. 전쟁 지역에서의 전염병 발생으로 인해 가격 상승, 공급망 차질, 그리고 아미노글리코사이드 수요 증가가 초래되었습니다. 이러한 요인들은 시장 수요 감소, 가격 상승, 공급망 교란을 야기하여 환자들이 필수적인 아미노글리코사이드 의약품을 구하기 어렵게 만들 것으로 예측됩니다.
또한, 경제 성장 둔화 및 의료 서비스 수요 감소와 같은 분쟁의 간접적인 영향도 시장의 비관적인 전망에 기여할 수 있습니다. 분쟁의 전체적인 영향 규모는 아직 알 수 없지만, 세계 아미노글리코사이드 산업이 심각한 타격을 입을 것은 분명합니다.

시장 세분화 분석
전 세계 아미노글리코사이드 시장은 제품 유형, 투여 경로, 적용 분야 및 지역별로 세분화됩니다.
겐타마이신 부문은 예측 기간 동안 전 세계 아미노글리코사이드 시장에서 지배적인 위치를 차지할 것으로 예상됩니다.
겐타마이신 부문은 2022년 아미노글리코사이드 시장의 약 27.3%를 차지하며 가장 높은 시장 점유율을 기록했습니다. 겐타마이신은 신체 여러 부위의 심각한 세균 감염 치료에 흔히 사용되는 항생제입니다. 심각한 감염에 대한 선호되는 치료제이며, 연구 개발 확대에 힘입어 시장이 성장하고 있습니다.
2022년에 발표된 "다양한 환자 집단에서의 겐타마이신 임상 약동학 및 그람 음성균 감염에 대한 최적 용량의 결과: 최신 검토"라는 연구는 성인과 생후 1개월 이상 소아, 중증 환자를 포함한 모든 연령대에서 체중 기준 7mg/kg의 일반적인 초기 용량의 효과를 강조합니다. 이러한 투여 기법을 사용하면 목표 치료 결과를 달성할 가능성이 더 높은 것으로 나타났습니다. 따라서 위의 요인들로 인해 해당 시장 부문은 예측 기간 동안 전 세계 아미노글리코사이드 시장에서 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
지역 분석
북미는 전 세계 아미노글리코사이드 시장에서 지배적인 위치를 차지하고 있습니다.
북미는 예측 기간 동안 전체 시장 점유율의 약 36.9%를 차지할 것으로 추정됩니다. 높은 가처분 소득, 주요 시장 참여 기업의 존재, 고령화 인구, 높은 세균 감염률, 항생제 내성 증가 등이 예측 기간 동안 북미 지역의 아미노글리코사이드 시장 성장을 견인할 주요 요인으로 예상됩니다.
아미노글리코사이드를 함유한 항생제 제제 시장은 여러 제조업체의 참여로 인해 크게 확대되고 있습니다. 특히 미국 기업인 파다기스(Padagis)는 2022년 3월 FDA로부터 AB 등급을 받은 토브라덱스(Tobradex) 안과용 현탁액의 제네릭 버전을 승인받으면서 중요한 이정표를 세웠습니다. 토브라마이신과 덱사메타손은 이 약물의 활성 성분입니다.
토브라덱스 안과용 현탁액은 주로 코르티코스테로이드가 필요한 염증성, 스테로이드 반응성 안질환 치료 및 표재성 세균성 안구 감염 위험이 있는 경우에 사용됩니다. 따라서 위와 같은 요인으로 인해 시장은 예측 기간 동안 성장할 것으로 예상됩니다.
경쟁 환경
시장의 주요 글로벌 업체로는 Pfizer Inc, Vega Pharma Ltd., Teva Pharmaceuticals USA, Inc., Huvepharma, Cipla Limited, Medson Pharmaceuticals, Medico Remedies Pvt. Ltd, Zoetis, AstraZeneca, Kremoint Pharma Pvt. Ltd. 등이 있습니다.
보고서 구매 이유

• 제품 유형, 투여 경로, 적용 분야 및 지역별 글로벌 아미노글리코사이드 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악하기 위함입니다.

• 트렌드 분석 및 공동 개발을 통해 상업적 기회를 파악합니다.

• 모든 세그먼트를 포함한 아미노글리코사이드 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 아미노글리코사이드 시장 보고서는 약 49개의 표, 53개의 그림, 195페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The global aminoglycosides market reached US$ 1,636.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 2,202.2 million by 2030. The global aminoglycosides market is expected to exhibit a CAGR of 3.8% during the forecast period (2023-2030).
The global aminoglycosides market is a thriving sector in the pharmaceutical industry, focusing on the treatment of severe bacterial infections. Aminoglycosides are significant antibiotics that are widely utilized in hospitals, clinics, and research laboratories. Recent market trends reveal an increase in demand for combination medicines as well as a noticeable emphasis on developing novel formulations. Significant developments in the global aminoglycosides market include R&D initiatives, regulatory approvals, and a rising application in veterinary medicine.
The growing prevalence of bacterial infections, the increasing aging population, and high antibiotic usage are the factors driving the global aminoglycoside market. The growing geriatric population is increasing the demand for aminoglycoside drugs. According to WHO 2022 projection, the global population aged 60 and up is expected to grow dramatically. By 2030, one in every six individuals worldwide will be 60 or older, with the population in this age group estimated to reach 1.4 billion, up from 1 billion in 2020.
Market Dynamics
The Rising Prevalence of Tuberculosis is Propelling the Growth of the Global Aminoglycoside Market.
The rising incidence of tuberculosis is one of the main factors driving the significant rise of the global aminoglycoside market. Strong antibiotics like aminoglycosides are necessary for the efficient treatment of tuberculosis, a serious bacterial illness. The need for aminoglycosides is growing as a result of the rising prevalence of tuberculosis, particularly in developing nations.
For instance, according to the Centers for Disease Control and Prevention report of 2023, in 2022, there were 8,300 reported cases of tuberculosis (TB) in the United States, resulting in a rate of 2.5 cases per 100,000 people. This is a modest rise from the 7,874 cases reported in 2021. In 2022, the incidence of tuberculosis remained at 2.5 incidents per 100,000 people.
The Growing Demand for Aminoglycoside in Veterinary Medicine is Driving the Growth of the Global Aminoglycoside Market.
The use of aminoglycosides in veterinary medicine has been continuously expanding, offering market players a lucrative opportunity. In livestock, companion animals, and aquaculture, aminoglycosides are commonly used to treat bacterial infections. These aminoglycosides are administered in-feed and in-water form in poultry and pig industries.
For instance, Mycoplasma and Escherichia coli are the most frequent causes of respiratory infections in poultry that need to be treated with aminoglycosides. Animals can be treated with aminoglycosides for bacterial infections Escherichia coli, Proteus, Pseudomonas, Salmonella, Shigella, Serratia, and Enterobacter. Owing to these reasons, veterinary medicine usage in bacterial infection will drive the global aminoglycosides market over the forecast period.
The Development of Drug Resistance is Hampering the Growth of the Global Aminoglycoside Market.
Antibiotic resistance is the ability of bacteria to tolerate the effects of antibiotics, rendering them useless in treating bacterial infections. Prolonged and inappropriate usage of aminoglycosides has contributed to the development of bacterial strains resistant to these antibiotics, decreasing their efficiency.
For instance, Methicillin-resistant Staphylococcus aureus (MRSA) and bacteria producing extended-spectrum beta-lactamase (ESBL) are becoming resistant to aminoglycosides. Infected patients' aminoglycoside resistance rates, phenotypes, and mechanisms have all been reported. Antibiotic-resistant bacteria, such as MRSA and ESBL-producing bacteria, are becoming a rising public health threat.
COVID-19 Impact Analysis
The COVID-19 outbreak has had a substantial influence on the global aminoglycosides industry. The pandemic disrupted worldwide supply chains and reduced demand for goods and services in a variety of industries, including the aminoglycosides industry. One of the most significant effects of COVID-19 on the aminoglycosides market is the disruption of supply chains, which has resulted in a decline in aminoglycoside antibiotic production.
The pandemic has also increased antibiotic usage, as individuals are becoming more concerned about their health and taking adequate prescriptions to avoid infections and lengthier hospital stays. However, aminoglycosides may have particular benefits in the fight against COVID-19. According to a 2021 paper published by the National Library of Medicine, aminoglycosides have the potential to be SARS-CoV-2 antivirals. In vitro, inhibition of murine hepatitis virus (MHV) was demonstrated by the aminoglycosides hygromycin B (hygB) and neomycin. Others discovered hygB activity against bovine and feline coronaviruses.
Russia-Ukraine Conflict Analysis
The conflict between Russia and Ukraine is expected to have a substantial influence on the global aminoglycoside market. Because of the incidence of infectious diseases in war zones, has led to higher pricing, supply chain interruptions, and increased demand for aminoglycosides. These factors are predicted to reduce market demand, raise prices, and disrupt the supply chain, making it difficult for patients to get essential aminoglycoside drugs.
Furthermore, the conflict's indirect effects, such as lower economic growth and lower demand for healthcare services, may contribute to the market's pessimistic view. While the full extent of the conflict's impact is unknown, it is clear that the global aminoglycosides industry will be severely impacted.
Segment Analysis
The global aminoglycosides market is segmented based on product type, route of administration, application, and region.
The Gentamicin Segment is expected to hold a Dominant Position for the Global Aminoglycoside Market over the Forecast Period.
The gentamicin segment accounted for the highest market share accounting for approximately 27.3% of the aminoglycoside market in 2022. Gentamicin is an antibiotic that is commonly used to treat severe bacterial infections in many regions of the body. It is the preferred treatment for serious infections, and its market expansion is being supported by expanded R&D.
A recent study conducted in 2022 and entitled "Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review" highlights the efficiency of a typical starting dose of 7 mg/kg based on total body weight in both adults and children older than one month, including critically ill patients. The likelihood of attaining the targeted treatment outcome is observed to be higher with this dosing technique. Thus, owing to the above factors, the market segment is expected to hold the largest market share for the global aminoglycoside market over the forecast period.
Geographical Analysis
North America holds a Dominant Position in the Global Aminoglycoside Market.
North America is estimated to hold around 36.9% of the total market share throughout the forecast period. The high disposable income, presence of major market players, an aging population, high prevalence of bacterial infections, and rising incidence of antibiotic resistance are some of the key factors expected to drive the aminoglycoside market in North America region over the forecast period.
The market for antibiotic formulations containing aminoglycosides is expanding significantly as a result of the involvement of several manufacturers in their creation. A significant milestone was reached by the U.S.-based company Padagis in March 2022 when the FDA gave the generic version of Tobradex ophthalmic suspension, which has an AB rating, the go-ahead. Tobramycin and dexamethasone make up this medication's active components.
Tobradex Ophthalmic Suspension is primarily used for the treatment of inflammatory, steroid-responsive ocular disorders where a corticosteroid is necessary, as well as when there is a risk of superficial bacterial ocular infection. Hence, owing to the above factors, the market is expected to drive over the forecast period
Competitive Landscape
The major global players in the market include Pfizer Inc, Vega Pharma Ltd., Teva Pharmaceuticals USA, Inc., Huvepharma, Cipla Limited, Medson Pharmaceuticals. Medico Remedies Pvt. Ltd, Zoetis, AstraZeneca, and Kremoint Pharma Pvt. Ltd., among others.
Why Purchase the Report?
• To visualize the global aminoglycosides market segmentation based on the product type, route of administration, application, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of aminoglycosides market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global aminoglycoside market report would provide approximately 49 tables, 53 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Route of Administration
3.3. Snippet by Application
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The Rising Prevalence of Tuberculosis is Propelling the Growth of the Global Aminoglycoside Market.
4.1.1.2. The Growing Demand of Aminoglycoside as Veterinary Medicine is Driving the Growth of the Global Aminoglycoside Market
4.1.2. Restraints
4.1.2.1. The Development of Drug Resistance is Hampering the Growth of the Global Aminoglycoside Market.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. By Product Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.1.2. Market Attractiveness Index, By Product Type
8.2. Neomycin*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Tobramycin
8.4. Gentamicin
8.5. Amikacin
8.6. Paromomycin
8.7. Streptomycin
8.8. Kanamycin
8.9. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Injectables*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Feed
9.4. Intra-mammary
9.5. Topical
9.6. Oral
10. By Application
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.1.2. Market Attractiveness Index, By Application
10.2. Veterinary*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Skin Infection
10.4. Respiratory diseases
10.5. UTI & Pelvic Diseases
10.6. Other Diseases
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.6.1. The U.S.
11.2.6.2. Canada
11.2.6.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.6.1. Germany
11.3.6.2. The U.K.
11.3.6.3. France
11.3.6.4. Italy
11.3.6.5. Spain
11.3.6.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.6.1. Brazil
11.4.6.2. Argentina
11.4.6.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.6.1. China
11.5.6.2. India
11.5.6.3. Japan
11.5.6.4. Australia
11.5.6.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Product Benchmarking
12.3. Company Share Analysis
12.4. Key Developments and Strategies
13. Company Profiles
13.1. Pfizer Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Vega Pharma Ltd.
13.3. Teva Pharmaceuticals USA, Inc.
13.4. Huvepharma
13.5. Cipla Limited
13.6. Medson Pharmaceuticals
13.7. Medico Remedies Pvt. Ltd
13.8. Zoetis
13.9. AstraZeneca
13.10. Kremoint Pharma Pvt.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Pfizer Inc., 4.	Key Developments, Vega Pharma Ltd., Teva Pharmaceuticals USA, Inc., Huvepharma, Cipla Limited, Medson Pharmaceuticals, Medico Remedies Pvt. Ltd, Zoetis, AstraZeneca, Kremoint Pharma Pvt.

표 목록 (Tables)

List of Tables

Table 1 Global Aminoglycosides Market Value, By Product Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Aminoglycosides Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Aminoglycosides Market Value, By Application, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Aminoglycosides Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Aminoglycosides Market Value, By Product Type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Aminoglycosides Market Value, By Product Type, 2021-2030 (US$ Million)

Table 7 Global Aminoglycosides Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Aminoglycosides Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 9 Global Aminoglycosides Market Value, By Application, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Aminoglycosides Market Value, By Application, 2021-2030 (US$ Million)

Table 11 Global Aminoglycosides Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Aminoglycosides Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Aminoglycosides Market Value, By Product Type, 2021-2030 (US$ Million)

Table 14 North America Aminoglycosides Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 North America Aminoglycosides Market Value, By Application, 2021-2030 (US$ Million)

Table 16 North America Aminoglycosides Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Aminoglycosides Market Value, By Product Type, 2021-2030 (US$ Million)

Table 18 South America Aminoglycosides Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 South America Aminoglycosides Market Value, By Application, 2021-2030 (US$ Million)

Table 20 South America Aminoglycosides Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Aminoglycosides Market Value, By Product Type, 2021-2030 (US$ Million)

Table 22 Europe Aminoglycosides Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 Europe Aminoglycosides Market Value, By Application, 2021-2030 (US$ Million)

Table 24 Europe Aminoglycosides Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Aminoglycosides Market Value, By Product Type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Aminoglycosides Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Aminoglycosides Market Value, By Application, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Aminoglycosides Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Aminoglycosides Market Value, By Product Type, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Aminoglycosides Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Aminoglycosides Market Value, By Application, 2021-2030 (US$ Million)

Table 32 Pfizer Inc: Overview

Table 33 Pfizer Inc: Product Portfolio

Table 34 Pfizer Inc: Key Developments

Table 35 Vega Pharma Ltd.: Overview

Table 36 Vega Pharma Ltd.: Product Portfolio

Table 37 Vega Pharma Ltd.: Key Developments

Table 38 Teva Pharmaceuticals USA, Inc.: Overview

Table 39 Teva Pharmaceuticals USA, Inc.: Product Portfolio

Table 40 Teva Pharmaceuticals USA, Inc.: Key Developments

Table 41 Huvepharma: Overview

Table 42 Huvepharma: Product Portfolio

Table 43 Huvepharma: Key Developments

Table 44 Cipla Limited: Overview

Table 45 Cipla Limited: Product Portfolio

Table 46 Cipla Limited: Key Developments

Table 47 Medson Pharmaceuticals: Overview

Table 48 Medson Pharmaceuticals: Product Portfolio

Table 49 Medson Pharmaceuticals: Key Developments

Table 50 Medico Remedies Pvt. Ltd: Overview

Table 51 Medico Remedies Pvt. Ltd: Product Portfolio

Table 52 Medico Remedies Pvt. Ltd: Key Developments

Table 53 Zoetis: Overview

Table 54 Zoetis: Product Portfolio

Table 55 Zoetis: Key Developments

Table 56 AstraZeneca: Overview

Table 57 AstraZeneca: Product Portfolio

Table 58 AstraZeneca: Key Developments

Table 59 Kremoint Pharma Pvt. Ltd.: Overview

Table 60 Kremoint Pharma Pvt. Ltd.: Product Portfolio

Table 61 Kremoint Pharma Pvt. Ltd.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 2 Global Aminoglycosides Market Share, By Product Type, 2022 & 2030 (%)

Figure 3 Global Aminoglycosides Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Aminoglycosides Market Share, By Application, 2022 & 2030 (%)

Figure 5 Global Aminoglycosides Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Aminoglycosides Market Y-o-Y Growth, By Product Type, 2022-2030 (%)

Figure 7 Neomycin Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 8 Tobramycin Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 9 Gentamicin Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 10 Amikacin Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 11 Paromomycin Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 12 Streptomycin Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 13 Global Aminoglycosides Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 14 Injectables Route of Administration in Global Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 15 Feed Route of Administration in Global Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 16 Intra-mammary Route of Administration in Global Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 17 Topical Route of Administration in Global Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 18 Oral Route of Administration in Global Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 19 Global Aminoglycosides Market Y-o-Y Growth, By Application, 2022-2030 (%)

Figure 20 Veterinary Application in Global Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 21 Skin Infection Application in Global Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 22 Respiratory Diseases Application in Global Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 23 UTI & Pelvic Diseases Application in Global Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 24 Global Aminoglycosides Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 25 North America Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 26 Asia-Pacific Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 27 Europe Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 28 South America Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 29 Middle East and Africa Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 30 North America Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 31 North America Aminoglycosides Market Share, By Product Type, 2022 & 2030 (%)

Figure 32 North America Aminoglycosides Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 33 North America Aminoglycosides Market Share, By Application, 2022 & 2030 (%)

Figure 34 North America Aminoglycosides Market Share, By Country, 2022 & 2030 (%)

Figure 35 South America Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 36 South America Aminoglycosides Market Share, By Product Type, 2022 & 2030 (%)

Figure 37 South America Aminoglycosides Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 38 South America Aminoglycosides Market Share, By Application, 2022 & 2030 (%)

Figure 39 South America Aminoglycosides Market Share, By Country, 2022 & 2030 (%)

Figure 40 Europe Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 41 Europe Aminoglycosides Market Share, By Product Type, 2022 & 2030 (%)

Figure 42 Europe Aminoglycosides Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 43 Europe Aminoglycosides Market Share, By Application, 2022 & 2030 (%)

Figure 44 Europe Aminoglycosides Market Share, By Country, 2022 & 2030 (%)

Figure 45 Asia-Pacific Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 46 Asia-Pacific Aminoglycosides Market Share, By Product Type, 2022 & 2030 (%)

Figure 47 Asia-Pacific Aminoglycosides Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 48 Asia-Pacific Aminoglycosides Market Share, By Application, 2022 & 2030 (%)

Figure 49 Asia-Pacific Aminoglycosides Market Share, By Country, 2022 & 2030 (%)

Figure 50 Middle East & Africa Aminoglycosides Market Value, 2021-2030 (US$ Million)

Figure 51 Middle East & Africa Aminoglycosides Market Share, By Product Type, 2022 & 2030 (%)

Figure 52 Middle East & Africa Aminoglycosides Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 53 Middle East & Africa Aminoglycosides Market Share, By Application, 2022 & 2030 (%)

Figure 54 Pfizer Inc: Financials

Figure 55 Vega Pharma Ltd.: Financials

Figure 56 Teva Pharmaceuticals USA, Inc.: Financials

Figure 57 Huvepharma: Financials

Figure 58 Cipla Limited: Financials

Figure 59 Medson Pharmaceuticals: Financials

Figure 60 Medico Remedies Pvt. Ltd: Financials

Figure 61 Zoetis: Financials

Figure 62 AstraZeneca: Financials

Figure 63 Kremoint Pharma Pvt. Ltd.: Financials

글로벌 아미노글리코사이드 시장 – 2023-2030

Global Aminoglycosides Market - 2023-2030